

TUNISIE

HAMMAMET

du 19 | nov.
au 21 | 2021

4^e édition

AFRAMED 2021

VIH, Hépatites, Santé sexuelle
Infections émergentes



www.aframed2021.org



Prise de poids, complications métaboliques et ARV


Gilles Wandeler

gilles.wandeler@insel.ch

Hammamet, 20.11.21




L'obésité en augmentation dans la population générale (NCD-RisC, n=129 mio.)






L'obésité en augmentation chez le PVVIH (Cohorte VIH Suisse, n=20,000)






Prise de poids et VIH: historique







Prise de poids et VIH: les facteurs de risque







Prise de poids et VIH: les facteurs de risque








Prise de poids sous ARV chez PVVIH naïfs (NA-ACCORD, n=22,972, dont 4,190 sous InSTI)





Prise de poids sous ARV chez PVVIH naïfs *(Pooled analysis of 8 Gilead clinical trials worldwide, n=5,680)*





—●— INSTI
 —×— PI
 —◇— NNRTI

—●— BIC
 —×— DTG
 —◇— EVG/c

—●— TAF
 —×— ABC
 —△— TDF
 —◇— ZDV





Prise de poids sous ARV chez PVVIH naïfs (ADVANCE, Afrique du Sud, n=1,053)







Prise de poids sous ARV après un switch (USA, n=495 sous FTC/TDF/EFV, maintien vs. switch vers InSTI)






Prise de poids sous ARV après un switch (Swiss HIV Cohort Study, n=4,375)





TAF et lipides


(Swiss HIV Cohort Study, n=4,375)






Prise de poids sous ARV: quels mécanismes?

(ADVANCE, Afrique du Sud, n=510 with genetic consent)




EFV metabolizer group
based on CYP2B6 genotype







Tissu adipeux et ARV: distribution plus importante que quantité (France, n=19 PLWH undergoing bariatric surgery)



67 y/o male


BMI 25 kg/m² and VAT 2.6 L/m²

53 y/o male

BMI 30 kg/m² and VAT 0.9 L/m²





Conséquences de la prise de poids sous ARV: Syndr. métabolique (ADVANCE, Afrique du Sud, n=1,053)






Conséquences de la prise de poids sous ARV: Diabète (EuroSIDA, n=6,721, 41% sous InSTI)






Conséquences de la prise de poids sous ARV: Stéatose hépatique ***(Swiss HIV Cohort Study, n=416, 55% sous TAF)***





Prise de poids sous ARV: quelles conséquences globales?

- Enjeu majeur: >50% des PVVIH avec ≥ 1 comorbidité dans 10 ans en Afrique sub-Saharienne
- Impact sur recommandations OMS: TDF vs. TAF?
- Données mettant en lien prise de poids (mesures, seuils) et son impact sur la santé en Afrique SS sont nécessaires!



Merci de votre attention!